

Proclamation 7207 of July 1, 1999

To Extend Nondiscriminatory Treatment (Normal Trade Relations Treatment) to Products of Mongolia and To Implement an Agreement To Eliminate Tariffs on Certain Pharmaceuticals and Chemical Intermediates

*By the President of the United States of America
A Proclamation*

1. The United States has had in effect a bilateral Agreement on Trade Relations with Mongolia since 1991 and has provided normal trade relations treatment to the products of Mongolia since that time. I have found Mongolia to be in full compliance with the freedom of emigration requirements of title IV of the Trade Act of 1974 (the “Trade Act”) (19 U.S.C. 2432).

2. Pursuant to section 2424(b)(1) of Public Law 106–36, and having due regard for the findings of the Congress in section 2424(a) of said Law, I hereby determine that title IV of the Trade Act (19 U.S.C. 2431–2441) should no longer apply to Mongolia.

3. On November 13, 1998, members of the World Trade Organization (WTO), including the United States and 21 other major trading countries, announced in the WTO an agreement to eliminate tariffs on certain pharmaceuticals and chemical intermediates that were the subject of reciprocal duty elimination negotiations during the Uruguay Round of Multilateral Trade Negotiations (the “Uruguay Round”). A similar agreement between the United States and 16 other major trading countries eliminating tariffs on enumerated pharmaceuticals and chemical intermediates was implemented for the United States on April 1, 1997, by Proclamation 6982, adding such goods to the scope of the agreement on pharmaceutical products reached at the conclusion of the Uruguay Round and reflected in Schedule XX–United States of America, annexed to the Marrakesh Protocol to the General Agreement on Tariffs and Trade (1994) (Schedule XX).

4. Section 111(b) of the Uruguay Round Agreements Act (URAA) (19 U.S.C. 3521(b)) authorizes the President to proclaim the modification of any duty or staged rate reduction of any duty set forth in Schedule XX for products that were the subject of reciprocal duty elimination negotiations during the Uruguay Round, if the United States agrees to such action in a multilateral negotiation under the auspices of the WTO, and after compliance with the consultation and layover requirements of section 115 of the URAA (19 U.S.C. 3524). Section 111(b) also authorizes the President to proclaim such modifications as are necessary to reflect such duty treatment in Schedule XX by means of rectifications thereof.

5. On April 29, 1999, pursuant to section 115 of the URAA, the United States Trade Representative (USTR) submitted a report to the Committee on Ways and Means of the House of Representatives and the Committee on Finance of the Senate (“the Committees”) that sets forth the proposed tariff eliminations, together with the advice received from the appropriate private sector advisory committee and the United States International Trade Commission regarding the proposed tariff eliminations. During the 60-day period thereafter, the USTR consulted with the Committees on the proposed actions.

6. Section 604 of the Trade Act, as amended (19 U.S.C. 2483), authorizes the President to embody in the Harmonized Tariff Schedule of the United States (HTS) the substance of the relevant provisions of that Act, and of other acts affecting import treatment, and actions thereunder, including the removal, modification, continuance, or imposition of any rate of duty or other import restriction.

7. Pursuant to section 111(b) of the URAA, I have determined that Schedule XX should be modified to reflect the implementation by the United States of the multilateral agreement on certain pharmaceuticals and chemical intermediates negotiated under the auspices of the WTO. In addition, I have determined that the pharmaceuticals appendix to the HTS should be modified to reflect the duty eliminations provided in such agreement, and to make certain minor technical corrections in the identification of particular products in order to ensure that products are accorded the intended duty treatment.

NOW, THEREFORE, I, WILLIAM J. CLINTON, President of the United States of America, acting under the authority vested in me by the Constitution and the laws of the United States, including but not limited to section 2424(b)(2) of Public Law 106–36, section 111(b) of the URAA, and section 604 of the Trade Act, do hereby proclaim that:

(1) Nondiscriminatory treatment (normal trade relations treatment) shall be extended to the products of Mongolia, which shall no longer be subject to title IV of the Trade Act.

(2) The extension of nondiscriminatory treatment to the products of Mongolia shall be effective as of the date of signature of this proclamation.

(3) In order to implement the multilateral agreement negotiated under the auspices of the WTO to eliminate tariffs on certain pharmaceutical products and chemical intermediates, and to make technical corrections in the tariff treatment accorded to such products, the HTS is modified as set forth in the Annex to this proclamation.

(4) Such modifications to the HTS shall be effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after the dates set forth in the Annex for the respective actions taken.

(5) Any provisions of previous proclamations and Executive orders that are inconsistent with the actions taken in this proclamation are superseded to the extent of such inconsistency.

IN WITNESS WHEREOF, I have hereunto set my hand this first day of July, in the year of our Lord nineteen hundred and ninety-nine, and of the Independence of the United States of America the two hundred and twenty-third.

WILLIAM J. CLINTON

Proc. 7207

Title 3—The President

ANNEX

MODIFICATIONS TO THE HARMONIZED TARIFF
SCHEDULE OF THE UNITED STATES

The Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, effective on the dates set forth for each annex section.

Section A. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after July 1, 1999, the following products are to be accorded duty-free treatment:

1. For subheadings 2905.22.50, 2910.30.00, 2921.43.40, 2922.19.20, 2924.29.05, and 2933.39.20, the Rates of Duty 1-Special subcolumn is modified by inserting, in alphabetical order, the symbol "K" in the parentheses following the "Free" rate of duty in such subcolumn for each such subheading.

2. The Pharmaceutical Appendix to the HTS is modified as provided below:

(a). Table 1 of the Appendix is modified by adding the following new INNs, in alphabetical order, in the "Product" column and their CAS numbers in the "CAS No." column:

| Product | CAS Number | Product | CAS Number |
|-------------------------|-------------|------------------------|-------------|
| *abacavir | 136470-78-5 | eperezolid | 165800-04-4 |
| abafungin | 129639-79-8 | eplerenone | 107724-20-9 |
| abarelix | 183552-38-7 | epitilbamide | 148031-34-9 |
| abiraterone | 154229-19-3 | fabesetron | 129300-27-2 |
| acrezast | 123548-56-1 | fandofloxacin | 164150-99-6 |
| agomelatine | 138112-76-2 | faralimomab | 167816-91-3 |
| alatrofloxacin | 157182-32-5 | fasidotril | 135038-57-2 |
| alinastine | 154541-72-7 | fasoracetam | 110958-19-5 |
| almotriptan | 154323-57-6 | felvizumab | 167747-20-8 |
| almuride | 61136-12-7 | fenofenadine | 83799-24-0 |
| amelomelastone | 123013-22-9 | fidarestat | 136087-85-9 |
| amlintide | 122384-88-7 | filaminast | 141184-34-1 |
| apadoline | 135003-30-4 | flibanserlin | 167933-07-5 |
| arctumomab | 154361-48-5 | folitropin beta | 150490-84-9 |
| aripiprazole | 129722-12-9 | fomivirsen | 144245-52-3 |
| arolyline | 36145-07-8 | forasartan | 145216-43-9 |
| aseripide | 153242-02-5 | foropafant | 136468-36-5 |
| asimadoline | 153205-46-0 | frovatriptan | 158747-02-5 |
| atiprimod | 123018-47-3 | fudosteine | 13189-98-5 |
| atizoram | 136537-46-6 | fulvestrant | 129453-61-8 |
| atipirofen | 108912-17-0 | fuomine | 142996-66-5 |
| atreleuton | 154355-76-7 | gacyclidine | 68134-81-6 |
| aviptadil | 40077-57-4 | ganaxolone | 38398-32-2 |
| aviriptan | 151140-96-4 | gatifloxacin | 160738-57-8 |
| avorelin | 140703-49-7 | gavestinel | 153436-22-7 |
| avotermin | 182212-66-4 | glaspimod | 134143-28-5 |
| bamaquimast | 135779-82-7 | glutofamide | 132682-98-5 |
| basiliximab | 179045-86-4 | hemoglobin crosfumaryl | 142261-03-8 |
| becaplermin | 165101-51-9 | ibutamoren | 159634-47-6 |
| bectumomab | 158318-63-9 | icopezil | 145508-78-7 |
| belaperidone | 156862-51-0 | igovomab | 171656-50-1 |
| beloxepin | 135628-30-2 | indinavir | 150378-17-9 |
| bepotastine | 126602-71-3 | indisectron | 141549-75-9 |
| bibapcicite | 153507-46-1 | infiximab | 170277-31-3 |
| biricodar | 159997-94-1 | insulin aspart | 116094-23-6 |
| blonanserin | 132810-10-7 | insulin glargine | 160337-95-1 |
| bracofensine | 171655-91-7 | interferon alfacon-1 | 118390-30-0 |
| brinzolamide | 138890-62-7 | iocanilic acid (123 I) | 74855-17-7 |
| carafiban | 177563-40-5 | ioflupane (123 I) | 155798-07-5 |
| cariporide | 159138-80-4 | iometopane (123 I) | 136794-86-0 |
| cedelizumab | 156586-90-2 | ipamorelin | 170851-70-4 |
| ceftiozime alapivoxil | 135821-54-4 | iroplact | 154248-96-1 |
| celgospir | 121104-96-9 | israpafant | 117279-73-9 |
| cemadotin | 159776-69-9 | ivabradine | 155974-00-8 |
| cervasiatin | 145598-86-6 | keliximab | 174722-30-6 |
| cetermin | 157238-32-0 | lagatide | 157476-77-2 |
| cevimefine | 107233-08-9 | landiolol | 133242-30-5 |
| choriogonadotropin alfa | 177073-44-8 | lanepitant | 170566-84-4 |
| cizolirine | 142165-43-9 | lasinavir | 175385-62-3 |
| clenoliximab | 162912-58-9 | ledoxantrone | 113457-05-9 |
| clevidipine | 166432-28-6 | lefradafiban | 149503-79-7 |
| clevudine | 163252-36-6 | levocetirizine | 130018-77-8 |
| colessevelam | 182815-43-6 | levosalbutamol | 34391-04-3 |
| dabelotene | 118976-38-8 | licostinel | 153504-81-5 |
| daicolidine | 120958-90-9 | linetastine | 159776-68-8 |
| danaparoid sodium | 83513-48-8 | linezolid | 165800-03-3 |
| daniplestim | 161753-30-6 | linitript | 136381-85-6 |
| dapilant | 153438-48-4 | lintuzumab | 166089-32-3 |
| declopramide | 891-60-1 | lirexapride | 145414-12-6 |
| delibant | 140661-97-8 | lodenosine | 110143-10-7 |
| dexefaroxan | 143249-88-1 | lotrafiban | 171049-14-2 |
| dexsotalol | 30238-32-9 | lumefantrine | 82186-77-4 |
| dionepezil | 120014-06-4 | lurtotecan | 149882-10-0 |
| dronedarone | 141626-36-0 | mazokalm | 164178-54-5 |
| droxinavir | 159910-86-8 | melagatran | 159776-70-2 |
| dutasteride | 164656-23-9 | meluadrine | 134865-33-1 |
| ecenofloxacin | 162301-05-5 | mespiperone (11 C) | 94153-50-1 |
| edrecolomab | 156586-89-9 | metesind | 138384-68-6 |
| efavirenz | 154598-52-4 | milacinamide | 141725-10-2 |
| elaclidar | 143664-11-3 | milameline | 139886-32-1 |
| eldacimibe | 141993-70-6 | | |
| elotriptan | 143322-58-1 | | |
| elinafide | 162706-37-8 | | |
| embusartan | 156001-18-2 | | |
| emoctakin | 142298-00-8 | | |
| eniluracil | 59989-18-3 | | |
| enlimomab pegol | 169802-84-0 | | |
| ensaculin | 155773-59-4 | | |

Proclamations

Proc. 7207

Annex (con.)

-2-

Section A (con.)

2. (con.)

(a). (con.)

| Product | CAS Number | Product | CAS Number |
|----------------------|-------------|---------------------------------|-------------|
| milfasartan | 148564-47-0 | ritonavir | 155213-67-5 |
| milodisim | 137463-76-4 | rituximab | 74722-31-7 |
| minalrestat | 129688-50-2 | rivastigmine | 123441-03-2 |
| minodronic acid | 127657-42-5 | rizatriptan | 144034-80-0 |
| miproxifene | 129612-87-9 | robalzotan | 169758-66-1 |
| mitiglinide | 145375-43-5 | roflumilast | 162401-32-3 |
| mivobulin | 122332-18-7 | rosiglitazone | 122320-73-4 |
| moxifloxacin | 151096-09-2 | roxifiban | 170902-47-3 |
| moxilubant | 146978-48-5 | rupatadine | 158876-82-5 |
| nagrestipen | 166089-33-4 | sabcomeline | 59912-53-5 |
| nateglinide | 105816-04-4 | samarium (153 Sm) leixidronam | 154427-83-5 |
| nelfinavir | 159989-64-7 | sampatrilat | 129981-36-8 |
| nelzarabine | 121032-29-9 | saredutant | 142001-63-6 |
| nepadutant | 183747-35-5 | scopinast | 145574-90-9 |
| nepafenac | 78281-72-8 | seocalcitol | 134404-52-7 |
| nepaprazole | 156601-79-5 | sevelamer | 32757-95-6 |
| nepicastat | 173997-05-2 | sibrafiban | 172927-75-0 |
| nerelimomab | 162774-06-3 | sildenafil | 139755-83-2 |
| nifekalant | 130636-43-0 | silperisone | 140944-31-6 |
| nolatrexed | 147149-76-6 | sinapultide | 138531-07-4 |
| nolpitanium besilate | 155418-06-7 | sinitroil | 143248-63-9 |
| nonacog alfa | 113478-33-4 | sipatrigine | 130800-90-7 |
| oberadilol | 114856-44-9 | sitafloxacin | 127254-12-0 |
| omapatrilat | 167305-00-2 | sivelestat | 127373-66-4 |
| omiloxetine | 176894-09-0 | sorbetolide | 130403-08-6 |
| opanixil | 152939-42-9 | sulesomab | 167747-19-5 |
| opratorium iodide | 146919-78-0 | sunepitron | 148408-65-5 |
| oprelvekin | 145941-26-0 | taltirelin | 103300-74-9 |
| orazipone | 137109-78-5 | talviraline | 169312-27-0 |
| orbofiban | 163250-90-6 | targinine | 17035-90-4 |
| osanetant | 160492-56-8 | tasonermin | 94948-59-1 |
| osutidine | 140695-21-2 | tazomeline | 131987-54-7 |
| pagoclone | 133737-32-3 | technetium (99m Tc) nofetumomab | 165942-79-0 |
| palinavir | 154612-39-2 | merpentan | 157476-76-1 |
| palonosetron | 135729-56-5 | technetium (99m Tc) pintumomab | 178959-14-3 |
| pamaqueside | 150332-35-7 | technetium (99mTc) apcitide | 173324-94-2 |
| pamiteplase | 151912-42-4 | temiverine | 110221-53-9 |
| paricalcitol | 131918-61-1 | temocaprilat | 49979-74-8 |
| pegmusirudin | 186638-10-8 | terbogrel | 147650-57-5 |
| peldesine | 133432-71-0 | tererstigmine | 154413-61-3 |
| pelubipofen | 69956-77-0 | ticolubant | 148883-56-1 |
| pemetrexed | 137281-23-3 | tifacogin | 159098-79-0 |
| perifosine | 157716-52-4 | tilnoprofen arbamei | 137332-54-8 |
| pexiganan | 172820-23-4 | tivirapine | 151287-22-8 |
| pibutidine | 103922-33-4 | tobacillin | 131094-16-1 |
| pifonakin | 112721-39-8 | trafermin | 80288-69-1 |
| pleconaril | 153168-05-9 | trastuzumab | 148998-94-1 |
| pralmorelin | 158861-67-7 | trecovirsen | 160677-67-8 |
| pramlintide | 151126-32-8 | tresperimus | 95268-62-5 |
| pranazepide | 150408-73-4 | upenazime | 99821-47-3 |
| pregabalin | 148553-50-8 | urokinase alfa | 175865-60-8 |
| prucalopride | 179474-81-8 | valganciclovir | 101312-92-9 |
| pumaprazole | 158364-59-1 | valnemulin | 121584-18-7 |
| quetiapine | 111974-69-7 | valsopodar | 116308-55-5 |
| quilostigmine | 139314-01-5 | vatanidipine | 141575-50-0 |
| ralitrexed | 112887-68-0 | vedacilidine | 162652-95-1 |
| ranelic acid | 135459-90-4 | vinflunine | 135354-02-8 |
| rapacuronium bromide | 156137-99-4 | xaliproden | 149820-74-6 |
| resocortol | 76675-97-3 | xemilofiban | 107452-89-1 |
| retigabine | 150812-12-7 | ziconotide | 123760-07-6 |
| revatropate | 149926-91-0 | zinostatin stimalamer | 139264-17-8 |
| rifalazil | 129791-92-0 | zolmitriptan | |
| rismorelin | 146706-68-5 | | |

(b). Table 2 of the Appendix is modified by adding the following chemical or INN derivative names in alphabetical order:

| | |
|------------|-----------------|
| *BENZOATE | MONOBENZOATE |
| DIFUMARATE | TETRAISOPROPYL* |
| DIPVOXIL | |

(c). Table 3 of the Appendix is modified by adding the following product names, in alphabetical order, along with their CAS numbers:

| Product | CAS Number |
|---|-------------|
| *(S)-but-3-yn-2-ol | 2914-69-4 |
| 2-(4-fluorobenzyl)thiophene | 63877-96-3 |
| 5-amino-N,N'-bis[2-(acetoxymethyl)ethyl]-2,4,6-triiodoisophthalamide | 148051-08-5 |
| 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide | 76801-93-9 |
| (S)-alpha-chloroformylethyl acetate | 36394-75-9 |
| diethyl dipropylmalonate | 6065-53-0 |
| 5-methyl-N-(4-(sulfamoyl)phenethyl)pyrazine-2-carboxamide | 33288-71-0 |
| (5aR,11bS)-9,10-dimethoxy-2-propyl-4,5,5a,6,7,11b-hexahydrobenzo[fl]thieno[2,3-c]-quinoline hydrochloride | 178357-37-4 |
| methyl N-(phenoxycarbonyl)-L-valinate | 153441-77-1 |
| (+)-6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-4H-[1,3]thiazeto-[3,2-a]quinoline-3-carboxylic acid | 112984-60-8 |
| methyl 3-amino-4,6-dibromo-o-toluate | 119916-05-1 |
| 4,6-dibromo-3-fluoro-o-toluic acid | 119916-27-7 |
| 7-bromo-1-cyclopropyl-6-fluoro-5-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 119916-34-6 |

Annex (con.)

-3-

Section A. (con.)

2. (con.)

(c). (con.)

ProductCAS Number

| | |
|--|-------------|
| 2-mercapto-5-(trifluoromethyl)anilinium chloride | 4274-38-8 |
| 2-(3-bromophenoxy)tetrahydropyran | 57999-49-2 |
| 6-chloro-5-(2-chloroethoxy)indol-2(3H)-one | 118289-55-7 |
| 6-chloroindol-2(3H)-one | 56341-37-8 |
| 6-methoxy-1,2,3,4-tetrahydro-1-naphthone | 1078-19-9 |
| N-[N-(tert-butoxycarbonyl)-L-alanyl]-L-alanine hydrate | 90303-36-9 |
| 2,2'-dithiodibenzonitrile | 33174-74-2 |
| 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]benzoic acid | 194602-23-8 |
| 1-methyl-4-nitro-3-propylpyrazol-5-carboxamide | 139756-01-7 |
| (S)-2-(4-fluorophenyl)-3-methylbutyric acid | 55332-37-1 |
| (3-benzimidazol-2-yl)propylmethylamine | 64137-52-6 |
| 7-chloro-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one | 2886-65-9 |
| 2-bromo-4-chloro-2-(2-fluorobenzoyl)acetanilide | 1584-62-9 |
| 2-benzoyl-2-bromo-4-chloroacetanilide | 41526-21-0 |
| (RS)-serinohydrazide hydrochloride | 55819-71-1 |
| 2,3,4-trihydroxybenzaldehyde | 2144-08-3 |
| dimethyl chloromalonate | 28568-76-0 |
| 4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidinyl | 150728-13-5 |
| 4-tert-butylbenzenesulfonamide | 6292-59-7 |
| methyl 3-[(methoxycarbonylmethyl)sulfamoyl]thiophene-2-carboxylate | 106820-63-7 |
| methyl 4-hydroxy-2-methyl-2H-thieno[2,3-e][1,2]thiazine-3-carboxylate 1,1-dioxide | 59804-25-0 |
| tert-butyl (1S,9S)-6,10-dioxo-9-phthalimidooctahydropyridazo[1,2-a][1,2]diazepine-1-carboxylate | 106628-72-7 |
| ethyl (R)-2-hydroxy-4-phenylbutyrate | 90315-82-5 |
| 1-benzyl hydrogen (S)-4-phthalimidoglutarate | 88784-33-2 |
| (S)-1-(benzyloxycarbonyl)hexahydropyridazine-3-carboxylic acid | 65632-62-4 |
| methyl ((1S,2R)-1-benzyl-3-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)decahydro-2-isouquinolyl]-2-hydroxypropyl)carbamate | 178680-13-2 |
| (3S,4aS,8aS)-2-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-tert-butyldecahydroisouquinoline-3-carboxamide | |
| 136522-17-3 | |
| 4-[(S)-3-amino-2-oxopyrrolidin-1-yl]benzonitrile hydrochloride | 175873-08-2 |
| ethyl 3-[(S)-1-(4-(N-2-hydroxyamidino)phenyl)-2-oxopyrrolidin-3-yl]ureido)propionate | 175873-10-6 |
| 4-[5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide | 169590-42-5 |
| 4-hydrazonobenzenesulfonamide hydrochloride | 17852-52-7 |
| 4-aminosuccinamic acid hydrochloride | 149177-92-4 |
| ethyl (S)-3-aminopent-4-ynoate hydrochloride | 154772-45-9 |
| 11-alpha-hydroxy-7-alpha-(methoxycarbonyl)-3-oxopregn-4-ene-21,17-alpha-carbolactone | 192704-56-6 |
| 11-alpha-hydroxy-3-oxopregna-4,6-diene-21,17-alpha-carbolactone | 73726-56-4 |
| 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide | 181695-72-7 |
| 5-methyl-3,4-diphenyl-4,5-dihydroisoxazol-5-ol | 181695-73-1 |
| N-[4-(5-methyl-3-phenylisoxazol-4-yl)phenylsulfon]propionamide, sodium salt | 198470-85-8 |
| pivaloyloxymethyl 7-[(Z)-2-[2-(tert-butoxycarbonylamino)thiazol-4-yl]pent-2-enamido]-3-(carbamoyloxymethyl)-3-cephem-4-carboxylate | 105989-80-3 |
| benzhydriol 6-(4-methylbenzamido)penicillanic acid 4-oxide | 77887-68-4 |
| benzhydriol 7-[(Z)-2-[2-(tert-butoxycarbonylamino)thiazol-4-yl]-4-(3-methylbut-2-enyloxycarbonyl)but-2-enamido]-3-cephem-4-carboxylate | 174781-17-2 |
| N-(2-quinolylcarbonyl)-L-asparagine | 136465-98-0 |
| methyl N-(methoxycarbonyl)-L-phenylalaninate | 41844-1-7 |
| N-[(2,6-diisopropylphenoxy)sulfonyl]-2-(2,4,6-trisopropylphenyl)acetamide | 166518-60-1 |
| (2S,3S)-3-methyl-2-(3-oxo-2,3-dihydro-1,2-benzisothiazol-2-yl)valeric acid | 177785-47-6 |
| (1S,4R)-1-azabicyclo[2.2.1]heptan-3-one O-[(Z)-(3-methoxyphenyl)ethynyl]oxime-maleic acid (1:1) | 180050-34-4 |
| N-[(R)-3-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-h]indol-3-yl]isonicotinamide | 179024-48-7 |
| 4-acetamido-2-aminobenzanilide | 112527-64-2 |
| N,N-bis(3-(ethylamino)propyl)propane-1,3-diamine tetrahydrochloride | 156886-85-0 |
| ethyl 5-(but-3-enyl)thiophene-2-carboxylate | 208337-82-0 |
| ethyl 5-(3R)-3,4-dihydroxybutylthiophene-2-carboxylate | 208337-83-1 |
| ethyl 5-(3R)-4-amino-3-hydroxybutylthiophene-2-carboxylate | 208337-84-2 |
| ethyl 5-(3R)-4-(tert-butoxycarbonylamino)-3-hydroxybutylthiophene-2-carboxylate | 186521-38-0 |
| ethyl 5-(3R)-4-(tert-butoxycarbonylamino)-3-(mesyloxy)butylthiophene-2-carboxylate | 186521-39-1 |
| ethyl 5-(3S)-3-(acetylthio)-4-(tert-butoxycarbonylamino)butylthiophene-2-carboxylate | 186521-40-4 |
| dimethyl 2-[(S)-1-(tert-butoxycarbonylamino)methyl]-2-(5-ethoxycarbonyl-2-thienyl)propylthio]malonate | 186521-41-5 |
| methyl (S)-6-[2-[5-ethoxycarbonyl]-2-thienyl]ethyl-3-oxo-1,4-thiazinane-2-carboxylate | 186521-42-6 |
| ethyl (6S)-5-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]thiophene-2-carboxylate | 186521-44-8 |
| (6S)-5-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]thiophene-2-carboxylic acid | 186521-45-9 |
| diethyl N-[5-[2-[(6S)-2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]-2-phenyl]-L-glutamate | 177575-19-8 |
| 4-chloropyridine hydrochloride | 7379-35-3 |
| 4-phenoxypyridine | 4783-86-2 |
| 4-(4-pyridyloxy)benzenesulfonic acid | 192329-80-9 |
| 4-(4-pyridyloxy)benzenesulfonyl chloride hydrochloride | 192330-49-7 |
| (3S)-2,2-dimethyl-1,4-thiazinane-3-carboxylic acid | 84915-43-5 |
| (3S)-2,2-dimethyl-4-[4-(4-pyridyloxy)phenylsulfonyl]-1,4-thiazinane-3-carboxylic acid | 192329-83-2 |
| 2-amino-5-bromo-6-methylquinazolin-4(1H)-one | 147149-89-1 |
| 3-acetoxy-o-toluic acid | 168899-58-9 |
| (4R,5R)-4,5-bis(mesyloxymethyl)-1,3,2-dioxathiolane 2,2-dioxide | 208338-09-4 |
| (2R,3R)-1,4-bis(mesyloxymethyl)-2,3-diol | 1947-02-2 |
| 3,7,11-trimethyldodeca-1,6,10-trien-3-ol | 7212-44-4 |
| (6E,10E,14E)-3,7,11,15-tetramethylhexadeca-1,6,10,14-tetraen-3-ol | 1113-21-9 |
| methyl 4-amino-5-nitro-o-anisate | 59338-84-0 |
| methyl 5-(ethylsulfonyl)-o-anisate | 62140-67-4 |
| methyl 5-sulfamoyl-o-anisate | 33045-53-2 |
| 3-methoxy-5-sulfamoyl-o-anisic acid | 66644-80-2 |
| 1-benzylpiperidine-4-carbaldehyde | 22065-85-6 |
| [(E)-3-[(6R,7R)-7-amino-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]allyl]-1-(carbamoylmethyl)ethylmethyldiammonium | 160115-08-2 |
| [4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methanol | 118175-10-3 |
| (Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxy)imino]acetic acid | 116833-10-4 |
| 2-[ethyl(methylamino)acetamide | 116833-20-6 |
| 4-chloro-2-[(Z)-(methoxycarbonyl)methoxyimino]-3-oxobutyric acid | 84080-70-6 |
| 2-(5-ethyl-2-pyridyl)ethanol | 5223-06-3 |
| 2-(4-aminophenoxy)methyl-2,5,7,8-tetramethyl-4-oxochroman-6-yl acetate | 107188-37-4 |
| chloromethyl pivalate | 18997-19-8 |
| 7-ethyl-3-[2-(trimethylsilyloxy)ethyl]indole | 186453-69-8 |
| 5-amino-2,4,6-triodosophtalic acid | 35453-19-1 |
| 4-hydroxyindole | 2380-94-1 |
| thiazolidine 2,4-dione | 7295-31-0 |
| 2-bromo-3-methylthiophene | 14282-76-9 |
| 5-methyluracil | 65-71-4 |

Proclamations

Proc. 7207

Annex (con.)

-4-

Section A. (con.)

2. (con.)

(c). (con.)

| Product | CAS Number |
|---|-------------|
| thymidine | 50-89-5 |
| 3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridylmethanol | 103577-66-8 |
| 3-(cyanoimino)-3-piperidinopropionitrile | 56488-00-7 |
| N-acetyl-3-(3,4-dimethoxyphenyl)-DL-alanine | 27313-65-1 |
| 2,5,7,8-tetramethyl-2-(4-nitrophenoxy)methyl-4-oxochroman-6-yl acetate | 107188-34-1 |
| methyl 4-(bromomethyl)-m-anisate | 70264-94-7 |
| 9-bromononyl 4,4,5,5-pentafluoropentyl sulfide | 148757-89-5 |
| 2-(phenylthio)aniline | 1134-84-7 |
| 4,4,5,5,5-pentafluoropentan-1-ol | 148043-73-6 |
| methyl (S)-2-amino-4-(1H-tetrazol-5-yl)butyrate | 127105-49-1 |
| (3-chloro-4-fluorophenyl)[7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl]amine | 184475-35-2 |
| 5-hydroxy-1,2,3,4-tetrahydro-1-naphthone | 28315-83-7 |
| (R)-1-chloro-2,3-epoxypropane | 51594-55-9 |
| methyl 4-acetamido-o-anisate | 4093-29-2 |
| 4-acetamido-5-chloro-o-anisic acid | 24201-13-6 |
| methyl (1S,2S)-1-benzyl-3-chloro-2-hydroxypropylcarbamate | 176972-62-6 |
| ethyl 2-chloronicotinate | 1462-94-4 |
| ethyl 6-chloronicotinate | 49608-01-7 |
| 6-hydroxynicotinic acid | 5006-66-6 |
| 6-chloronicotinic acid | 5326-23-8 |
| 1-acetyl-piperazine | 13869-98-0 |
| 8-azaspiro[4.5]decane-7,9-dione | 1075-89-4 |
| (S)-2-(4-((2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)(prop-2-ynyl)amino)-2-fluorobenzamido)-4-(1H-tetrazol-5-yl)butyric acid | 153537-73-6 |
| SC-59735 | 116638-33-6 |
| SC-70935 | 193700-51-5 |
| 6,7-dichloro-2,3-dimethoxyquinoxalin-5-ylamine | 178619-89-1 |
| 4-(2-methyl-1H-imidazol-4,5-c[pyridin-1-yl])benzoic acid | 132026-12-1 |
| methyl(4-nitrophenethyl)amine hydrochloride | 166943-39-1 |
| 2-chloroethyl 4-nitrophenyl ether | 3363-72-0 |
| (2R,3SR)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (1R,4S)-2-oxobornane-10-sulfonic acid (1:1) | 188416-34-4 |
| 6-ethyl-5-fluoropyrimidin-4(1H)-one | 137234-87-8 |
| diphenyl[(S)-pyrrolidin-3-yl]acetone nitrile hydrobromide | 194602-27-2 |
| (2,3-dihydrobenzofuran-5-yl)acetic acid | 69999-16-2 |
| cyclohexylammonium 1-[(S)-2-(tert-butoxycarbonyl)-3-(2-methoxyethoxy)propyl]-cyclopentanecarboxylate | 167944-94-7 |
| cis-4-(benzyloxycarbonyl)cyclohexylammonium tosylate | 87299-45-0 |
| 5-bromo-3-[(R)-1-methylpyrrolidin-2-ylmethyl]indole | 143322-57-0 |
| meso-3-benzyl-6-nitro-3-azabicyclo[3.1.0]hexane | 151860-18-1 |
| diethyl (6-chloro-9H-carbazol-2-yl)methylmalonate | 171208-55-4 |
| beta-cyclodextrin sulfolbutyl ethers, sodium salts | 182410-00-0 |
| N-(2-chloroethyl)pyrrolidine hydrochloride | 7250-67-1 |
| 6,7-bis(2-methoxyethoxy)quinazolin-4(1H)-one | 179688-29-0 |
| ethyl 3,4-dihydroxybenzoate | 3943-89-3 |
| 3-[(2,1,4-(2-dimethylaminoethoxy)phenyl]-2-phenylbut-1-enyl]phenol | 83647-29-4 |
| 2-[1-(tert-butoxycarbonyl)-4-piperidyl]acetic acid | 157688-46-5 |
| 4-pyridylacetic acid hydrochloride | 6622-91-9 |
| a,a,a-trifluoro-4-nitro-m-toluidine | 393-11-3 |
| methyl 1-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxylate | 39925-10-5 |
| Na-(tert-butoxycarbonyl)-N'-nitro-L-arginine | 2188-18-3 |
| Na-(tert-butoxycarbonyl)-N-methoxy-N-methyl-N'-nitro-L-argininamide | 139976-34-4 |
| (2S,3S)-3-amino-2-ethoxy-N-nitropiperidine-1-carboxamide hydrochloride | 180280-77-5 |
| (S)-O-benzyl-lactaldehyde-N-(tert-butoxycarbonyl)hydrazone | 192802-28-1 |
| phenyl (4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl)carbamate | 184177-81-9 |
| [(3S,5S)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)]tetrahydrofuran-3-yl[methyl-4-chlorobenzenesulfonate] | 175712-02-4 |
| 8-chloro-11-(4-piperidylidene)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridine | 100643-71-8 |
| 2-hydroxy-2-methyl-4-nitro-3-(trifluoromethyl)propionanilide | 52806-53-8 |
| 5-acetyl-salicylamide | 40187-51-7 |
| 8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one | 31251-41-9 |
| 1-nitro-4-(1,2,2,2-tetrachloroethyl)benzene | 4714-32-3 |
| 3-chloropropyl dimethylammonium chloride | 5407-04-5 |
| 3-(trichlorovinyl)aniline hydrochloride | 81972-27-2 |
| 2-[1-(mercaptomethyl)cyclopropyl]acetic acid | 162515-68-6 |
| 3-(4-bromobenzyl)-2-butyl-4-chloro-1H-imidazol-5-ylmethanol | 151015-31-6 |
| 4-chloro-1-methylpiperidine hydrochloride | 5382-23-0 |
| methyl 2-[(S)-3-[(E)-3-(2-(7-chloro-2-quinolyl)vinyl)phenyl]-3-hydroxypropyl]benzoate | 181159-72-0 |
| methyl 2-[(S)-3-[(E)-3-(2-(7-chloro-2-quinolyl)vinyl)phenyl]-3-oxopropyl]benzoate | 148968-11-6 |
| 2-(2-trityl-2H-tetrazol-5-yl)phenylboronic acid | 143722-25-2 |
| (3aS,8aR)-3-[(2R,4S)-2-benzyl-4,5-epoxyvaleryl]-2,2-dimethyl-3,3a,8a-tetrahydro-2H-indeno[1,2-d]oxazole | 158512-24-4 |
| N[(4S,6S)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-yl]acetamide | 147086-83-7 |
| N[(4S,6S)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-yl] acetamide | 147200-03-1 |
| 5-iodouracil | 696-07-1 |
| N'-methyl-1H-pyrazole-1-carboxamide hydrochloride | 59184-35-3 |
| (S)-tetrahydrofuran-3-ol | 86087-23-2 |
| ethyl 4,6-dichloro-3-formylindole-2-carboxylate | 153435-96-2 |
| 3-oxoandrost-4-ene-17-beta-carboxylic acid | 302-97-6 |
| alpha, alpha, alpha, alpha', alpha', alpha'-hexafluoro-2,5-xylidine | 328-93-8 |
| (1-2-azabicyclo[2.2.1]hept-5-en-3-one | 61865-48-3 |
| (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one | 79200-56-9 |
| ((1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)cyclopent-2-enyl)methanol hydrochloride | 172015-79-1 |
| N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide | 171887-03-9 |
| 4-fluorobenzyl 4-methylthio phenyl ketone | 87483-29-2 |
| 2-amino-3-pyridyl methyl ketone | 65326-33-2 |
| 6-methoxy-1H-purin-2-ylamine | 20535-83-5 |
| 1-(beta-D-arabinofuranosyl)pyrimidine-2,4-(1H,3H)-dione | 3083-77-0 |
| (2R)-4-methyl-2-[(S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]valeric acid | 157918-70-2 |
| (S)-2-amino-3,3-dimethyl-N-2-pyridylbutylamide | 171764-07-1 |
| 3-nitro-4-pyridone | 5435-54-1 |
| 2,6-difluorobenzylamine | 69385-30-4 |
| L-ribose | 24259-69-4 |
| (5,6-dichloro-1H-benzimidazol-2-yl)isopropylamine | 175161-55-0 |
| (R)-2-amino-2-ethylhexan-1-ol | 151851-75-1 |
| 3-methylencyclobutanecarbonitrile | 15760-35-7 |
| 4-tert-butylbenzyl 2-((2R,3S)-3-[(R)-1-(tert-butylidimethylsilyloxy)ethyl]-2-[(1R,3S)-3-methoxy-2-oxocyclohexyl]-4-oxoazetidin-1-yl)-2-oxoacetate | 159593-17-6 |
| methyl (3aR,4R,7aR)-2-methyl-4-[(1S,2R)-1,2,3-triacetoxypropyl]-3a,7a-dihydro-4H-pyrano-[3,4-d]oxazole-6-carboxylate | 78850-37-0 |
| (4S,5R,6R)-5-acetamido-4-amino-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydropyran-2-carboxylic acid | 130525-62-1 |

Annex (con.)

-5-

Section A. (con.)

2. (con.)

(c). (con.)

| Product | CAS Number |
|--|-------------|
| pyrazole-1-carboxamide hydrochloride | 4023-02-3 |
| 2-acetoxy-5-acetylbenzyl acetate | 24085-06-1 |
| (R)-1,2,3,4-tetrahydropapaverine hydrochloride | 54417-53-7 |
| trans-2-chloro-3-[4-(4-chlorophenyl)cyclohexyl]-1,4-naphthoquinone | 153977-22-1 |
| 1,3-dichloroacetone | 534-07-6 |
| 3,5-dimethylpiperidine | 35794-11-7 |
| 2,6-diaminopyrimidin-4-ol | 56-06-4 |
| 1-(2-chloroethyl)piperidinium chloride | 2008-75-5 |
| diethyl L-glutamate hydrochloride | 1118-89-4 |
| tert-butyl 1-(R,4S)-4-(hydroxymethyl)cyclopent-2-enylcarbamate | 168960-18-7 |
| 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride | 151257-01-1 |
| tert-butyl 2-[[1-(2-aminothiazol-4-yl)-2-(benzothiazol-2-ylthio)-2-oxoethylidene] aminoxy]-2-methylpropionate | 89604-92-2 |
| bis[(isopropoxy)carbonyloxy]methyl [(R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl phosphonate-fumaric acid (1:1) | 202138-50-9 |
| (R)-[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methylphosphonic acid | 147127-20-6 |
| (R)-propylene carbonate | 16806-55-6 |
| 6-amino-9H-purin-9-ylethanol | 7051-34-5 |
| (R)-2-(6-amino-9H-purin-9-yl)-1-methylethanol | 14047-28-0 |
| chloromethyl isopropyl carbonate | 35180-01-9 |
| diethyl (tosyloxy)methylphosphonate | 31618-90-3 |
| (R)-5-chloropropane-1,2-diol | 57090-45-6 |
| (S)-[[trityloxy]methyl]oxirane | 129940-50-7 |
| (S)-2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol | 154598-58-0 |
| 10,10-bis[(2-fluoro-4-pyridyl)methyl]anthrone | 160588-45-4 |
| (S)-N-[(1S,2R)-3-[[1-(3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3,3-dimethyl-2-(sarcosylamino)butylamide | 183556-68-5 |
| (4R,5S,6S,7R)-1-[(3-amino-1H-indazol-5-yl)methyl]-4,7-dibenzyl-3-butyl-5,6-dihydroxyhexahydro-2H-1,3-diazepin-2-one | 188978-02-1 |
| (2S)-N-[(R)-1-(1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2-[4-[[4-methylpiperazin-1-yl)-carbonyl]phenoxy]-4-oxoazetidine-1-carboxamide | 157341-41-8 |
| 2-(piperazin-1-yl)pyrimidine | 20980-22-7 |
| 4-bromo-2,2-diphenylbutanenitrile | 39186-58-8 |
| bromomethylcyclopropane | 7051-34-5 |
| cyclobutanecarboxylic acid | 3721-95-7 |
| 2-phenyl-2-pyridylacetoneitrile | 5005-36-7 |
| 5-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one | 122852-75-9 |
| 4-(2-methyl-2-phenylhydrazino)-5,6-dihydro-2-pyridone | 138122-76-2 |
| 4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride | 28783-41-7 |
| methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)acetate hydrochloride | 130209-90-4 |
| 2-bromo-2-(2-chlorophenyl)acetic acid | 141109-25-3 |
| disodium (2S,3R)-2-hydroxy-3-isobutylsuccinate | 157604-22-3 |
| 7-amino-3-(2-furoylthiomethyl)-3-cephem-4-carboxylic acid | 80371-59-8 |
| methyl 5-chloro-o-anisate | 33924-48-0 |
| 4-[(4-mesylamino)phenyl]-4-oxobutyric acid | 100632-57-3 |
| benzyl 3-fluoro-4-morpholinophenylcarbamate | 168828-81-7 |
| (3R)-3-[(S)-1-(methylamino)ethyl]pyrrolidine | 155322-92-2 |
| (4-carboxybutyl)triphenylphosphonium bromide | 17814-85-6 |
| (3aS,9aS,9bR)-3a-methyl-6-[2-(2,5,5-trimethyl-1,3-dioxan-2-yl)ethyl]-1,2,4,5,8,9,9a,9b-octahydro-3aH-cyclopenta[1,naphthalene]-3,7-dione | 88128-61-4 |
| 2-amino-2',5'-dichlorobenzophenone | 2958-36-3 |
| 21-chloro-16- α -methylpregna-1,4,9(11)-triene-3,20-dione | 151265-34-8 |
| 3,20-dioxopregna-1,4,9(11),16-tetraen-21-yl acetate | 37413-91-5 |
| uracil | 66-22-8 |
| tetrabutylammonium (6-iodo-1H-purin-2-yl)amide | 156126-48-6 |
| (1S,2S,3S)-2,3-bis(benzoyloxymethyl)cyclobutanol | 132284-17-8 |
| 5-methyluridine | 1463-10-1 |
| benzyl (1-carbamoyl-2-hydroxypropyl)carbamate | 91558-42-8 |
| 5,8-dihydro-1-naphthol | 27673-48-9 |
| potassium (R)-N-(3-ethoxy-1-methyl-3-oxoprop-1-enyl)-2-phenylglycine | 961-69-3 |
| triethylamine | 33881-72-0 |
| 1-[4-(2-dimethylaminoethoxy)[14C]phenyl]-1,2-diphenylbutan-1-ol | 82407-94-1 |
| o-chlorothiophenol | 6320-03-2 |
| cytidine 5-(dihydrogen phosphate) | 63-37-6 |
| 2-[benzyl(methyl)amino]ethyl acetoacetate | 54527-65-0 |
| 2-methyl-1-nitrosoindoline | 85440-79-5 |
| inosine 5'-disodium phosphate | 4691-65-0 |
| 4-[1-hydroxy-2-(methylamino)ethyl]phenol-L-tartaric acid (2:1) | 16589-24-5 |
| 4-phenylpiperidin-4-ol | 40807-61-2 |
| 1-(4-benzoyloxyphenyl)-2-(4-hydroxy-4-phenyl-1-piperidyl)propan-1-one | 188591-61-9 |
| 7-chloro-2-(4-methoxy-2-methylphenyl)-2,3-dihydro-5H-pyridazino[4,5-b]quinoline-1,4,10-trione, sodium salt | 170142-29-7 |
| N-[N-methoxycarbonyl-L-valyl]-N-[(S)-3,3,3-trifluoro-1-isopropyl-2-oxopropyl]-L-prolinamide | 182073-77-4 |
| 3-methyl hydrogen 7-chloro-1,4-dihydro-4-oxoquinoline-2,3-dicarboxylate | 170143-39-2 |
| (S)-N-[5-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-1H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]-2-thenoyl]-L-glutamic acid | 177575-17-6 |
| (S)-2,2-dimethyl-N-hydroxy-4-[4-(4-pyridyloxy)phenylsulfonyl]-1,4-thiazinane-3-carboxamide urate oxidase | 192329-42-3 |
| (Z)-1-[3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]hexahydro-1H-azepine hydrochloride | 9002-12-4 |
| (Z)-N-[3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]-N-ethylcyclohexylamine hydrochloride | 139592-99-7 |
| trans-2-fluoro-4-hydroxybaldone O-[(2Z)-2-(dimethylamino)ethyl]oxime-fumaric acid (2:1) | 132173-07-0 |
| N,N-diethyl-2-methyl-N-(6-phenyl-5-propylpyridazin-3-yl)propane-1,2-diamine-fumaric acid (2:3) | 130550-02-8 |
| 2-[[1-(7-chloro-4-quinolyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonylamino]-adamantane-2-carboxylic acid | 137733-33-6 |
| (S)-N-[4-(4-acetamido-4-phenyl-1-piperidyl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide-fumaric acid (1:1) | 146362-70-1 |
| N-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-2,3-dihydro-1H-indol-2-ylcarbonyl]-L-prolinamide | 176381-97-8 |
| 1-(6-chloro-2-pyridyl)-4-piperidylamine hydrochloride | 150375-75-0 |
| ethyl [(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthyl)-acetate hydrochloride | 77145-61-0 |
| methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)- α -D-glucopyranosyl-(1,4)-O-beta-D-glucopyranuronosyl-(1,4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)- α -D-glucopyranosyl-(1,4)-O-2-O-sulfo- α -D-glucopyranuronosyl-(1,4)-2-deoxy-2-(sulfoamino)-6-(hydrogensulfate)- α -D-glucopyranoside, decasodium salt | 121524-09-2 |
| 3-[[4-(4-amidinophenyl)thiazol-2-yl][1-(carboxymethyl)-4-piperidyl]amino]propionic acid | 114870-03-0 |
| ethyl 3-[(4-[4-(N-ethoxycarbonylamidino)phenyl]thiazol-2-yl)[1-(ethoxycarbonylmethyl)-4-piperidyl]amino]propionate | 180144-61-0 |
| (S)-1-[2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenacyl)-3-piperidyl]ethyl]-4-phenyl-1-azoniabicyclo[2.2.2]octane chloride | 190841-79-3 |
| 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidino-1H-pyrazole-3-carboxamide | 153050-21-6 |
| (R)-N-[1-[3-(1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl)propyl]-4-phenyl-4-piperidyl]-N-methyl- | 168273-06-1 |

Proclamations

Proc. 7207

Annex (con.)

-6-

Section A. (con.)

2. (con.)

(c). (con.)

Product

CAS Number

| | |
|--|-------------|
| acetamide hydrochloride | 173050-51-6 |
| dibenzyl 1-(2,4-difluorophenyl)-2-((1H-1,2,4-triazol-1-yl)-1-(1H-1,2,4-triazol-1-ylmethyl)ethyl phosphate | 194602-25-0 |
| (S)-2-(3-(2-fluorobenzyl)sulfonylamino)-2-oxo-2,3-dihydro-1-pyridyl-N-(1-formyl-4-guadinobutyl)acetamide | 179524-67-5 |
| 4-(4-(4-((3R,5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-ylmethoxy)phenyl)piperazin-1-yl)phenyl-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-1,2,4-triazol-5(4H)-one | 171228-49-2 |
| 4-(4-((1R)-3,10-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidinocarbonylmethyl)piperidine-1-carboxamide | 193275-84-2 |
| 4-(4-((1S)-3,10-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidinocarbonylmethyl)piperidine-1-carboxamide | 193275-85-3 |
| N-(1-ethyl-1,4-diphenylbut-3-enyl)cyclopropanecarboxamide | 137246-21-0 |
| (1S,3S,4S)-1-azabicyclo[2.2.1]heptan-3-ol | 142034-92-2 |
| (±)-1-azabicyclo[2.2.1]heptan-3-one | 21472-89-9 |
| ethyl 3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl acetate | 112733-28-5 |
| 2,6-diisopropylphenyl sulfamate | 92050-02-7 |
| diethyl (1-cyano-3-methylbutyl)malonate | 186038-82-4 |
| 2-imino-1,3-thiazol-4-one | 556-90-1 |
| 3,5-di-tert-butyl-4-hydroxybenzaldehyde | 1620-99-0 |
| N-(biphenyl-2-yl)-4-(2-methyl-4,5-dihydro-1H-imidazo[4,5-d][1]benzazepin-6-yl)carbonylbenzamide | 79528-39-3 |
| 3-(aminomethyl)-5-methylhexanoic acid | 128013-69-4 |
| 2-(2,4,6-triisopropylphenyl)acetic acid | 4276-85-1 |
| N,N-[dithiobis(o-phenylene)carbonyl]bis-L-isoleucine | 182149-25-3 |
| (1R,4S)-1-azabicyclo[2.2.1]heptan-3-one | 142034-97-7 |
| 3-amino-7-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one | 70890-50-5 |
| 1-ethyl-1,4-diphenylbut-3-enylamine | 129140-12-1 |
| sodium 1,2,3-triazole-5-thiolate | 59032-27-8 |
| (3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine hydrochloride | 183319-69-9 |
| 1-[(1S,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-4-phenylpiperidin-4-ol methanesulfonate trihydrate | 189894-57-3 |
| (5R,6S)-6-phenyl-5-[4-(2-pyrrolidinoethoxy)phenyl]-5,6,7,8-tetrahydro-2-naphthol-(1)-tartaric acid (1:1) | 190791-29-8 |
| 1-[(S)-3-(acetylthio)-2-methylpropionyl]-L-proline | 64838-55-7 |
| 4-benzoyloxy-2-[(1-methyl-2-phenoxyethyl)amino]propiophenone hydrochloride | 35205-50-6 |
| 5-(3-dimethylaminopropyl)-10,11-dihydrodibenz[a,d]cyclohepten-5-ol | 1159-03-1 |
| 2-aminoethylmethylamine | 100-36-7 |
| isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E)-(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate | 157283-68-6 |
| 21-benzoyloxy-9-α-fluoro-11-β,17-α-dihydroxy-16-α-methylpregna-1,4-diene-3,20-dione | 150587-07-8 |
| pilocarpine | 92-13-7 |
| atropine | 51-55-8 |
| 4-nitrobenzyl (4R,5R,6S)-3-(diphenoxyposphoryloxy)-6-[(R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate | 90776-59-3 |
| 2-aminopropane-1,3-diol | 534-03-2 |
| methyl 4-(bromomethyl)benzoate | 2417-72-3 |
| 2-butylimidazole-5-carbaldehyde | 68282-49-5 |
| ethyl hydrogen (2-phenylmethyl)malonate | 143468-96-6 |
| 4-(2-butyl-5-formylimidazol-1-ylmethyl)benzoic acid | 152146-59-3 |
| 2,6-dichloro-4-methylnicotinonitrile | 875-35-4 |
| 3,5-diacetamido-2,4,6-triiodobenzoic acid dihydrate | 50978-11-5 |
| 2,2,2-trifluoroethanol | 75-99-8 |
| 13-ethyl-17-α-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one oxime | 53016-31-2 |
| estropipate | 7280-37-7 |
| 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide | 180200-68-4 |
| 17-α-hydroxy-3,20-dioxopregna-4,9(11)-diene-21-yl acetate | 7753-60-8 |
| hemocyanins, megathura crenulata, reaction products with 1-O-[O-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)-O-(N-acetyl-alpha-neuraminosyl)-(2,3)-O-beta-D-galactopyranosyl-(1,4)-O-beta-D-glucopyranose | 195993-11-4 |
| 1-(28-[O-D-apio-beta-D-furanosyl-(1,3)-O-beta-D-xylopyranosyl-(1,4)-O-6-deoxy-alpha-L-mannopyranosyl-(1,2)-4-O-5-[5-α-L-arabinofuranosyloxy-3-hydroxy-6-methyloctanoyloxy]-3-hydroxy-6-methyloctanoyl]-6-deoxy-beta-D-galactopyranosyloxy]-16-α-hydrox | 141256-04-4 |
| 1-O-[O-(N-acetyl-alpha-neuraminosyl)-(2,3)-O-[O-beta-D-galactopyranosyl-(1,3)-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)]-O-beta-D-galactopyranosyl-(1,4)]-beta-D-glucopyranosylceramide | 104443-62-1 |
| 1-O-[O-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)-O-(N-acetyl-alpha-neuraminosyl)-(2,3)-O-beta-D-galactopyranosyl-(1,4)-beta-D-glucopyranosyl]ceramide | 104443-57-4 |
| N-[(1R,2R)-1-[O-(N-acetyl-alpha-neuraminosyl)-(2,3)-O-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)-O-beta-D-galactopyranosyl-(1,4)]-beta-D-glucopyranosyloxymethyl]-2-hydroxy-3-formylpropyl]stearamide | 196085-62-8 |
| ferristene | 155773-56-1 |
| codeine phosphate hemihydrate | 41444-52-6 |
| trans-1-benzoyl-4-phenyl-L-proline | 120851-71-0 |
| 5-methyluridine hemihydrate | 26954-21-6 |
| 5-benzoyl-2',3'-didehydro-3'-deoxythymidine | 122567-97-9 |
| 3',5'-anhydrothymidine | 38313-48-3 |
| 4-(benzoyloxycarbonyl)-4'-demethylepipodophyllotoxin | 23363-33-9 |
| 2,3,4,6-tetra-O-benzyl-1-O-(trimethylsilyl)-β-D-glucose | 80312-55-6 |
| 2,3,4,6-tetra-O-benzyl-D-glucose | 4132-28-9 |
| 6-iodo-1H-purin-2-ylamine | 19690-23-4 |
| (1R,2R,3S)-2-amino-9-[2,3-bis(benzoyloxymethyl)cyclobutyl]-9H-purin-6-one | 156126-12-3 |
| (1RS,2RS,3SR)-2,3-bis(benzoyloxymethyl)cyclobutylamine | 151807-53-3 |
| (1RS,2RS,3RS)-2,3-bis(benzoyloxymethyl)cyclobutanol | 127759-90-4 |
| (1R,2R,3S)-9-[2,3-bis(benzoyloxymethyl)cyclobutyl]-6-iodo-9H-purin-2-ylamine | 156126-89-3 |
| (2S,3S)-2,3-bis(benzoyloxymethyl)cyclobutanone | 132294-16-7 |
| (S)-5-(1,3-dioxolan-4-yl)-2-aminovaleric acid | 170242-34-9 |
| N,N-bis(trifluoroacetyl)-DL-homocystine | 105996-54-1 |
| (S)-2-(acetylthio)-3-phenylpropionic acid-dicyclohexylamine (1:1) | 157521-26-1 |
| methyl (4S,7S,10aS)-4-amino-5-oxocahydro-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylate | 167304-98-5 |
| 4-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-ylmethyl)biphenyl-2-carbonitrile | 136401-24-6 |
| DL-5-(1,2-dithiolan-3-yl)valeramide | 3206-73-3 |
| 4-(4-methoxyphenyl)butan-2-one | 104-20-1 |
| tetraisopropyl methylenediphosphonate | 1660-85-3 |
| (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid | 74163-81-8 |
| (S)-N-tert-butyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride | 149057-17-0 |
| (S)-N-tert-butyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide sulfate | 186537-30-4 |
| (3S)-tetrahydrofuran-3-yl (1S,2R)-3-[(4-aminophenylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate | 161814-49-9 |
| 6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione | 149950-60-7 |
| (2R,5S)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one | 143491-57-0 |
| 3'-azido-2',3'-dideoxy-5-methylcytidine hydrochloride | 108895-45-0 |

Proc. 7207

Title 3—The President

Annex (con.)

-7-

Section A. (con.)

2. (con.)

(c). (con.)

Product

CAS Number

(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-ylmethanol

145514-04-1

(4R,5S,6S,7R)-1,3-bis(3-aminobenzyl)-4,7-dibenzyl-5,6-dihydroxyhexahydro-2H-1,3-diazepin-2-one dimethanesulfonate

177932-89-7"

Section B. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after April 1, 1997, the following technical corrections are made to the enumerated subheading:

1. For subheading 2918.13.50, the Rates of Duty 1-Special subcolumn is modified by inserting, in alphabetical order, the symbol "K" in the parentheses following the "Free" rate of duty in such subcolumn.

2. The Pharmaceutical Appendix to the HTS is modified by adding to Table 3 of the Appendix the following product, with the product name inserted in alphabetical order in the "Product" column and its Chemical Abstracts Service (CAS) registry number in the "CAS No." column:

"1-(N2-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-N6-trifluoroacetyllysyl)proline

103300-91-0"

Section C. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after January 1, 1995, the following technical corrections are made to the enumerated subheadings:

For subheadings 2904.90.47, 2917.39.30, 2918.29.20, 2935.00.05, and 3402.20.10, the Rates of Duty 1-Special subcolumn is modified by inserting, in alphabetical order, the symbol "K" in the parentheses following the "Free" rate of duty in such subcolumn for each such subheading.

Proclamation 7208 of July 7, 1999

To Facilitate Positive Adjustment to Competition From Imports of Lamb Meat

By the President of the United States of America

A Proclamation

1. On April 5, 1999, the United States International Trade Commission (USITC) transmitted to the President a unanimous affirmative determination in its investigation under section 202 of the Trade Act of 1974, as amended (the “Trade Act”) (19 U.S.C. 2252), with respect to imports of fresh, chilled, or frozen lamb meat, provided for in heading 0204 of the Harmonized Tariff Schedule of the United States (HTS). Under section 202 of the Trade Act, the USITC determined that such lamb meat is being imported into the United States in such increased quantities as to be a substantial cause of the threat of serious injury to the domestic industry producing a like or directly competitive article. Further, the USITC, pursuant to section 311(a) of the North American Free Trade Agreement Implementation Act (the “NAFTA Implementation Act”) (19 U.S.C. 3371(a)), made negative findings with respect to imports of lamb meat from Canada and Mexico. The USITC also transmitted to the President its recommendation made pursuant to section 202(e) of the Trade Act with respect to the action that would address the threat of serious injury to the domestic industry and be most effective in facilitating the efforts of the domestic industry to make a positive adjustment to import competition.

2. Pursuant to section 203 of the Trade Act (19 U.S.C. 2253), and after taking into account the considerations specified in section 203(a)(2) of the Trade Act, I have determined to implement action of a type described in section 203(a)(3). However, pursuant to section 312(a) of the NAFTA Implementation Act (19 U.S.C. 3372(a)), I have determined that imports from Canada and Mexico, considered individually, do not account for a substantial share of total imports and do not contribute importantly to the threat of serious injury found by the USITC. Accordingly, pursuant to section 312(b) of the NAFTA Implementation Act (19 U.S.C. 3372(b)), I have excluded lamb meat the product of Canada or Mexico from the action I am taking under section 203 of the Trade Act.

3. Such action shall take the form of a tariff-rate quota on imports of fresh, chilled, or frozen lamb meat, provided for in HTS subheadings 0204.10.00, 0204.22.20, 0204.23.20, 0204.30.00, 0204.42.20, and 0204.43.20, imposed for a period of 3 years plus 1 day, with annual increases in the within-quota quantities in the second and third years, as provided for in the annex to this proclamation.

4. Except for products of Canada, Mexico, Israel, beneficiary countries under the Caribbean Basin Economic Recovery Act (CBERA) and the Andean Trade Preference Act (ATPA), and other developing countries that have accounted for a minor share of lamb meat imports, which shall all be excluded from this restriction, such tariff-rate quota shall apply to imports of lamb meat from all other countries and the in-quota quantity in each year shall be allocated among such countries. Pursuant to section 203(a)(1)(A) of the Trade Act (19 U.S.C. 2253(a)(1)(A)), I have further determined that these actions will facilitate efforts by the domestic industry to make a posi-